Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 9Head & Neck 8Gastrointestinal 8Thoracic 5Sarcoma 5Gynecologic 5Endocrine 5CNS 3Breast 3Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2NET 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Plasma Cell 1Hematologic Neoplasms 1

Interventions

Cytarabine 117Cyclophosphamide 88Etoposide 59Daunorubicin 58fludarabine phosphate 50Specimen Handling 49Methotrexate 49Filgrastim 48Vincristine 47Biopsy 47Rituximab 43Radiotherapy 34Dexamethasone 34Peripheral Blood Stem Cell Transplantation 32Doxorubicin 29Mitoxantrone 27Idarubicin 27Busulfan 27Azacitidine 27Prednisone 26Mercaptopurine 26Leucovorin 26fludarabine 25Decitabine 24Asparaginase 24venetoclax 23merphos 22Bortezomib 22Cyclosporine 20alvocidib 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Fluorodeoxyglucose F18 × Other hematologic neoplasm × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT00070239 2013-12-16

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

National Cancer Institute (NCI)

Phase 1 Terminated
100 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡